

Understanding and Treating Angina Postangioplasty

Editorial

Understanding and treating angina postangioplasty - *M. Marzilli, K. Fox, R. Ferrari* 175

Lead Article

Understanding and treating angina occurring after angioplasty - *A. Huqi, M. Marzilli* 177

Expert Answers to Three Key Questions

Syndrome X: how should it be investigated and treated? - *C. M. Webb, P. Collins* 191

What is the role of interventional procedures in the management of refractory angina pectoris? - *R. de Silva* 196

Is there a role for the nurse specialist in the management of complex angina? - *C. Wright* 209

Fascinoma Cardiologica

Trails of Discovery: Unbreak my heart: a short history of the defibrillator and CPR - *W. J. Sullivan Jr* 217

Summaries of Ten Seminal Papers - *M. Marzilli* 223

Physiologic basis for assessing critical coronary stenosis: instantaneous flow response and regional distribution during coronary hyperemia as measures of coronary flow reserve
K. L. Gould and others

Obstructive coronary atherosclerosis and ischemic heart disease: an elusive link! - *M. Marzilli and others*

Optimal medical therapy with or without PCI for stable coronary disease - *W. E. Boden and others*

Coronary artery disease as clogged pipes: a misconceptual model - *M. B. Rothberg*

Low diagnostic yield of elective coronary angiography
M. R. Patel and others

2013 ESC guidelines on the management of stable coronary artery disease - *C. Montalescot and others*

Quantitative relationship between the extent and morphology of coronary atherosclerotic plaque and downstream myocardial perfusion - *M. Naya and others*

Do clinical trials in ischemic heart disease meet the needs of those with ischemia? - *D. Morrone and others*

Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events - *L. Jespersen and others*

Stress testing after complete and successful coronary revascularization - *A. Huqi and others*

Bibliography of One Hundred Key Papers 235

Editors in Chief

Ferrari R, MD, PhD
Chair of Cardiology
University Hospital of Ferrara, Cona (Ferrara),
Italy

Fox K, MD, FRCP
National Heart and Lung Institute
Institute of Cardiovascular Medicine and Science
Royal Brompton Hospital, London, UK

Consulting Editors

Anand I, MD
Prof Medicine
La Jolla, CA, USA

Avkiran M, PhD
Cardiovascular Research
The Rayne Institute
St Thomas' Hospital
London, UK

Bassand JP, MD
Dept of Cardiology
University Hospital Jean Minjot
Besançon, France

Bertrand ME, MD
Hôpital Cardiologique
Lille, France

Böhm M, MD
Saarland University Hospital
Homburg/Saar, Germany

Bolli R, MD
Division of Cardiology
University of Louisville
Louisville, KY, USA

Borer JS, MD
Howard Gilman Institute for
Heart Valve Disease
Schivone Institute for Cardio-
vascular Translational Research
State University of New York
Downstate Medical Center,
New York, NY, USA

Coats A, MD
Faculty of Medicine
University of Sydney
Sydney, Australia

Cowie M, MD, PhD
Dept of Clinical Cardiology
National Heart & Lung Institute
London, UK

Danchin N, MD
Dept of Cardiology
Hôpital Européen
Georges Pompidou
Paris, France

Dargie HJ, MD
Cardiac Research
Western Infirmary
Glasgow, UK

Erol C, MD
Ankara University
Faculty of Medicine
Ankara, Turkey

Fox KA, MD
Dept of Cardiological Research
University of Edinburgh
Edinburgh, UK

Fuster V, MD, PhD
Cardiovascular Institute
Mount Sinai Medical Center
New York, NY, USA

Hasenfuss G, MD
Dept of Cardiology
Georg-August Universität
Göttingen, Germany

Heusch G, MD, PhD
West German Heart and
Vascular Centre Essen
Institute for Pathophysiology
University of Essen Medical
School
Essen, Germany

Hori M, MD, PhD
Dept of Internal Medicine
and Therapeutics
Osaka University Graduate
School of Medicine
Osaka, Japan

Hu D, MD
Heart Institute Intervention
Center
People Hospital of Peking
University
Beijing, China

Komajda M, MD
Dept of Cardiology
CHU Pitié-Salpêtrière
Paris, France

Libby P, MD
Cardiovascular Medicine
Brigham & Women's Hospital
Boston, MA, USA

Lonn E, MD
Hamilton Health Sciences
General Site
Hamilton, Ontario, Canada

Lüscher T, MD
Department of Cardiology
University Heart Center
University Hospital
Zürich, Switzerland

Lopez-Sendon JL, MD
CCU Dept of Cardiology
Hospital University
Gregorio Maranon
Madrid, Spain

Maggioni AP, MD
ANMC Research Center
Firenze, Italy

Marber MS, MD, PhD
Cardiovascular Research
The Rayne Institute
St Thomas' Hospital
London, UK

Oktay E, MD
Dept Cardiology
Dokuz Eylul University Faculty
of Medicine
İzmir, Turkey

Oto A, MD
Medical Office, Hacettepe
University School of Medicine
Ankara, Turkey

Patrono C, MD
Dept of Pharmacology
University La Sapienza
Rome, Italy

Pepine CJ, MD
Dept of Medicine
University of Florida
Gainesville, FL, USA

Pfeffer MA, MD, PhD
Dept Medicine
Brigham and Women's Hospital
Boston, MA, USA

Pinto F, MD
Cardiology Department
Faculdade de Medicina
Universidade de Lisboa
Lisbon, Portugal

Rapezzi C, MD
Institute of Cardiology
University of Bologna
Bologna, Italy

Rosen MR, MD
Dept of Pharmacology & Pediatrics
Columbia University College
of Physicians & Surgeons
New York, NY, USA

Ryden L, MD, PhD
Dept of Cardiology
Karolinska University
Hospital Solna
Stockholm, Sweden

Schneider MD, MD
Baylor College of Medicine
Houston, TX, USA

Seabra-Gomes RJ, MD
Instituto do Coracao
Hospital Santa Cruz
Carnaxide, Portugal

Shah A, MD
Cardiovascular Division
James Black Centre
British Heart Foundation Centre
of Excellence
King's College London
London, UK

Simoons ML, MD
Thoraxcenter
Erasmus University
Medical Center
Rotterdam, The Netherlands

Sipido K, MD, PhD
Dept Cardiovascular Sciences
Katholieke Universiteit Leuven
Leuven, Belgium

Steg PG, MD
Dept of Cardiology
Hôpital Bichat–Claude Bernard
Paris, France

Swedberg K, MD, PhD
Dept of Medicine
Sahlgrenska University
Hospital Ostra
Göteborg, Sweden

Tardif JC, MD
Montreal Heart Institute
Montreal,
Quebec, Canada

Tavazzi L, MD
Division of Cardiology
Policlinico San Matteo IRCCS
Pavia, Italy

Tendera M, MD
3rd Division of Cardiology
Silesian School of Medicine
Katowice, Poland

Vanhoutte PM, MD
Dept of Pharmacology
University of Hong Kong
Faculty of Medicine
Hong Kong, China

Widimsky P, MD, PhD
Vinohrady Cardiocenter
Charles University Hospital
Prague, Czech Republic

Wijns WC, MD
Cardiovascular Center Aalst
OLV Hospital,
Aalst, Belgium

Zamorano JL, MD
University Francisco de
Vitoria/Hospital Ramón y Cajal
Madrid, Spain

Editorial

Mario Marzilli, MD, PhD

Kim Fox, MD, FRCP

Roberto Ferrari, MD, PhD

UNDERSTANDING AND TREATING ANGINA POSTANGIOPLASTY

Angina pectoris is commonly perceived as the clinical manifestation of coronary atherosclerosis. Based on this assumption, diagnostic and therapeutic algorithms have focused on identifying and removing “ischemia-causing” coronary atherosclerotic obstructions. Diagnosis and treatment of stable ischemic heart disease have been driven by coronary anatomy, particularly since the advent of percutaneous coronary interventions, to the point that the diagnosis of angina pectoris was denied in patients with typical symptoms and objective evidence of myocardial ischemia when “significant” stenosis was not identified at angiography (“false positive”) and vice-versa.

Recently, evidence has strongly challenged this simplistic approach to ischemic heart disease. In this issue of *Dialogues in Cardiovascular Medicine*, **Alda Huqi** and **Mario Marzilli** discuss the new evidence and guidelines on understanding and treating angina postangioplasty. In patients undergoing provocative tests, those with an ischemic response to stress had a prevalence of coronary stenosis at invasive angiography that was similar to those with a negative response. In an international registry of patients undergoing noninvasive coronary angiography, those with typical angina had a prevalence of coronary stenosis similar to that of completely asymptomatic patients.

In patients with angina and “significant” coronary stenosis, the stenosis was removed by percutaneous coronary intervention in addition to optimal medical therapy. However, angina persistence occurred in 34% of patients at the 1-year follow-up despite removing the putative cause. The persistence of symptoms after the percutaneous or surgical removal of the presumed cause of angina has often been denied; therefore, the clinical relevance of persistent angina after “successful” coronary revascularization is underestimated. Recently, the negative prognostic impact of persistent angina has been documented. When diagnosed, angina occurring postangioplasty is attributed to incomplete coronary revascularization due to diffuse coronary atherosclerosis and/or





chronic total occlusions. However, similar rates of persistent angina and/or inducible myocardial ischemia have been reported in patients with no residual stenosis after a successful percutaneous coronary intervention.

In the meantime, the understanding of ischemic heart disease has evolved, and the European guidelines have included not only classic atherosclerotic obstructions, but also both microvascular dysfunction and coronary vasospasm among the possible causes of chronic angina pectoris. The guidelines have acknowledged that these multiple mechanisms may coexist in an individual patient. This new, multifactorial conception of chronic ischemic heart disease has several diagnostic and therapeutic implications, many of which are not fully understood and therefore not fully implemented. One of the immediate consequences of this new approach is the downgrading of the diagnostic role of coronary angiography. In fact, given that microvascular dysfunction and coronary vasospasm are not visible at routine angiography, invasive or noninvasive imaging of coronary anatomy will only be rarely necessary for the sole purpose of establishing or excluding the diagnosis of angina pectoris.

Along the same line of reasoning, the persistence of angina postangioplasty may not only be due to incomplete revascularization, but also to the coexistence of mechanisms that are not treated by a percutaneous coronary intervention, namely microvascular dysfunction and/or coronary vasospasm. Therefore, the persistence of angina after a percutaneous coronary intervention is nothing more than additional indirect evidence supporting the multifactorial nature of ischemic heart disease. If this interpretation is correct, given that angina persists in about one-third of percutaneous coronary intervention patients, an additional effort should be made to identify the cause(s) of angina before referring a patient for a potentially harmful revascularization procedure. This strategy could not only avoid inappropriate interventions, but it could also limit costs and complications, which would eventually improve the cost-benefit ratio of elective percutaneous coronary interventions that have so far been quite disappointing.

Three additional papers in this issue of *Dialogues in Cardiovascular Medicine* nicely expand this perspective. **Carolyn M. Webb** and **Peter Collins** summarize the diagnostic and therapeutic challenges of effort angina in patients without significant atherosclerotic obstructions, which was once diagnosed as Syndrome X and is now called microvascular angina. **Ranil de Silva** discusses the therapeutic options available for refractory angina. Finally, **Christine Wright** describes the role of a dedicated nurse specialist both in organizing the multidisciplinary treatment team and in generating a treatment plan for patients with refractory angina.

